EBIO – Eleven Biotherapeutics, Inc, a clinical-stage biotech company, hit the bottom after announcing that its investigational eye drop failed as a cure for allergic conjunctivitis.
|EBIO – Eleven Biotherepeutics, Inc|
|Fundamentals||Previously closed at||0.31|
|Analyst opinion||The recent stock sell-off’s seem to have hit the biotech company really hard, with EBIO hitting a new low, losing more than 90% in value as compared to last year. The failed- experimental eye-drop “isunakinra”, being the biggest reason for the price drop. However, just a week ago, the market cap of EBIO was as low as $5.3 million, which is way low compared to its cash balance reported at the end of Q3 last year which amounts to $46 million|
|Sentiments||Though EPS is negative, we can see that the EPS has improved compared to prior year. EBIO has good fundamentals with a P/S ratio of 7.04, a P/B ratio of 0.20, a P/C ratio of 0.12 and a Quick ratio of 6.20.|
|91% analysts have a buy opinion for the stock.|
|Social pulse||The social media pulse is 35% lower than normal.|